下载本文档
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDactolisibCat. No.: HY-50673CAS No.: 915019-65-7Synonyms: BEZ235; NVP-BEZ235分式: CHNO分量: 469.54作靶点: PI3K; mTOR; Autophagy作通路: PI3K/Akt/mTOR; Autophagy储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验
2、 DMSO : 5.2 mg/mL (11.07 mM; Need ultrasonic and warming)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 0.52 mg/mL (1.11 mM); Clear solution2. 请依序添加每种溶剂: 10% DMSO 90% corn oilSolubility: 0.52 mg/mL (1.11 mM); Clear solution1/4 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 D
3、actolisib (BEZ235)种双重 的 pan-class I PI3K 和 mTOR 抑制剂,作于 p110/ 和mTOR,IC50 分别为 4 nM/5 nM/7 nM/75 nM 和 20.7 nM。Dactolisib (BEZ235) 抑制 mTORC1 和 mTORC2。IC50 & Target p110 p110-H1047R p110-E545K p1104 nM (IC50) 4.6 nM (IC50) 5.7 nM (IC50) 5 nM (IC50)p110 p110 mTOR mTORC17 nM (IC50) 75 nM (IC50) 20.7 nM (IC
4、50)mTORC2 Autophagy体外研究 Dactolisib (BEZ235) potently inhibits PI3K in an ATP Competitive Manner. Dactolisib (BEZ235) (250 nM)significantly reduced the phosphorylation levels of the mTOR activated kinase p70S6K. Dactolisib (BEZ235)also leads to a reduction of S235/S236P-RPS6 levels with an IC50 of 6.
5、5 nM, suggesting that Dactolisib(BEZ235) can directly inhibit the mTOR kinase, as the kinase domain of mTOR is highly homologous to theone of class IA PI3K. The activity of Dactolisib (BEZ235) against mTOR is confirmed using a biochemicalmTOR K-LISA assay (IC50, 20.7 nM) 1. The IC50s of Dactolisib (
6、BEZ235) for HCT116, DLD-1, and SW480cell lines are 14.36.4, 9.01.5, and 12.01.6 nM, respectively 2.体内研究 Dactolisib (BEZ235) (45 mg/kg, p.o.) treatment induces colonic tumor regression in a GEM model forsporadic PIK3CA wild-type CRC 2. Dactolisib (BEZ235) (45 mg/kg) is administered to MENX rats (n=2
7、eachgroup) by oral gavage and animals are sacrificed 1 or 6 hours after treatment. Immunostains for P-AKT andP-S6 show considerable reduction of the two proteins, and particularly of P-S6, 6 hours after administrationof Dactolisib (BEZ235) when compares with PEG-treated rats. At 6 hours after treatm
8、ent, the pituitaryadenomas of Dactolisib (BEZ235)-treated rats has a proteomic profile significantly different from the tumorsof placebo-treated rats 3.PROTOCOLKinase Assay 1 PI3K, , and proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-lengthprotein p110 protein, with
9、 the exception of that also does not contain the last 20 amino acids. PI3K isproduced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for , , and isoforms) orpVL1393 (
10、for isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomicDNA using methods recommended by the vendor for production of the respective recombinant baculovirusesand proteins. Compounds are tested for their activity against PI3K using a Kinase-Glo assay. The kinaser
11、eaction is done in 384-well black plate. Each well is loaded with 50 nL of test items (in 90% DMSO) and 5 Lreaction buffer 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 3 mM MgCl2, 1 mM DTT, and 0.05% CHAPScontaining 10 g/mL PI substrate (L-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-gluc
12、oside) and the PI3K proteins (10, 25, 10, and 150 nM of p110, p110, p110, and p110, respectively)are then added. The reaction is started by the addition of 5 L of 1 M ATP prepared in the reaction buffer2/4 Master of Small Molecules 您边的抑制剂师www.MedChemEand ran for either 60 (for p110, p110, and p110)
13、or 120 min (for p110) and subsequently terminated bythe addition of 10 L Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescencedetection 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 2 HCT116 (PIK3CA mutant; ki
14、nase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K),and SW480 (PIK3CA wild-type) human CRC cell lines (ATCC) and isogenic DLD-1 PIK3CA mutant and wild-type cells are maintained in DMEM with 10% FBS and 1 Penicillin/Streptomycin. Cells are plated at differentinitial densities (HCT1
15、16: 3,000 cells/well, DLD-1: 5,500 cells/well, SW480: 4,500 cells/well, DLD-1 PIK3CAmutant: 7,000 cells/well, and DLD-1 PIK3CA wild-type: 9,000 cells/well) to account for differential growthkinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235 (10, 100, 1000 nM),and
16、drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after theinitial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96AQueous One Solution Cell Proliferation Assay. Cell viability after drug treatment is nor
17、malized to that ofuntreated cells also grown for 48 hours. IC50 values are calculated using 4 parameter nonlinear regression inGraphPad Prism 5 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 23 Tumor-bearing Apc CKO mice a
18、re randomly assigned to treatment with either control vehicle alone (n=8) or45 mg/kg body weight BEZ235 in 10% 1-methyl-2-pyrrolidone/90% PEG 300 (n=8) by daily oral gavage for28 days. The treatment dose is chosen based on literature indicating that 40-50 mg/kg body weight BEZ235effectively treats m
19、urine tumor models without adverse effects. Base on pharmacokinetic studiesdemonstrating maximal tissue concentration one hour after NVP-BEZ235 administration, tumor-bearing miceare sacrificed one hour after final treatment dose. Colonic tumor volume is assessed using calipers(widthlengthheight) and
20、 tumors are harvested for both western blot analysis and immunohistochemistry.Rats 3MENX-affected rats used. Three doses of BEZ235 are tested in MENX rats: 20, 30, and 45 mg/kg. As the twohigher doses causes a weight loss 10% after 10 days of treatment, the dose of 20 mg/kg is used for furtherstudie
21、s. For MRI studies, MENX-affected rats at 7 to 8 months of age (with sizeable adenomas but still ingood general health) are treated for 14 days with BEZ235 (20 mg/kg) or placebo (PEG) administered dailyper oral gavage.MCE has not independently confirmed the accuracy of these methods. They are for re
22、ference only.户使本产品发表的科研献 Nature. 2018 Aug;560(7719):499-503. Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Nat Commun. 2017 Jun 8;8:15617. Leukemia. 2014 Sep;28(9):1819-27. Cell Syst. 2018 Dec.See more customer validations on HYPERLINK / www.MedChemE3/4 Master of Small Molecules 您边的抑制剂师www.MedChemEREFERENCES1. Maira SM, et al. Identification and characterization of NVP-BEZ235, a ne
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 建筑装饰工程室内装饰色彩搭配考核试卷
- 毛发染整行业法律法规与合规管理考核试卷
- 期货市场风险管理工具比较服务考核试卷
- 物理安全与监控系统集成考核试卷
- 电机在电力工程建设的应用考核试卷
- 建筑装饰用轻质铝蜂窝板考核试卷
- 大跨空间结构设计高级研修班结业考试
- 专题17期末复习之书面表达16篇(重庆名校真题)七年级英语下学期期末复习查缺补漏冲刺满分(人教版)
- 大气课程设计后记
- 初中数学实验课程设计
- 宫颈息肉病历书写模板
- 人民币教具正反面完美打印版
- 工伤保险医疗待遇审核
- 左迁至蓝关示侄孙湘(韩愈)PPT通用课件
- DB45∕T 396-2022 膨胀土地区建筑技术规程
- 医生类抖音代运营方案
- 排水管道工程施工组织设计
- 家长沟通记录表格
- USB-Type-C-基础知识培训讲义PPT课件
- 桥梁桩基钢筋笼吊装计算书
- 新人教版三年级数学上册教学计划+进度表
评论
0/150
提交评论